Company intelligence / Profile preview

PiMedBio

Not specified, Gyeonggi-do, South Koreapimedbio.com ↗

Ownership: Private
Development stage: Other

Overview

PiMedBio is developing first-in-class oncology therapeutics, with its lead asset PMB212 targeting cancer stemness. The company leverages a proprietary platform to identify optimal drug candidates, focusing on precise molecular and cellular targets involved in disease progression. As of early 2025, its most advanced programs are in preclinical or discovery stages, with no clinical trial results yet reported[2][3].

Therapeutic areas: OncologyImmunologyGastroenterology
Modalities: Small molecule drugsBiological products[3]
Industry: Biotech

Drug pipeline

3 assets

PMB212

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

No major partnerships disclosed as of May 2025. Participated in JLABS Korea innovation ecosystem, which may indicate collaborations or incubator support[4].

Beyond the preview

Go deeper on PiMedBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PiMedBio.

Explore the full profile